The National Heart, Lung, and Blood Institute (NHLBI) is planning a second competitive renewal for the Production Assistance for Cellular Therapies (PACT) program for the development of clinical manufacturing protocols and production of novel somatic (biological) cell therapies for use in pre-clinical studies to be used in support of Investigational New Drug (IND) applications. The objective of this program is to continue to advance cellular therapy research in the areas of regeneration of damaged/diseased tissues, organs, biologic systems, and targeted treatments for serious diseases without effective therapies. This program will fund up to eight (8) geographically dispersed Cell Processing Facilities (CPFs) and one (1) Coordinating Center (CC) in the U.S. with the capacity to provide consulting, manufacturing, preclinical study, administrative, and regulatory expertise necessary for the development of novel cellular therapies in the area of heart, lung, and blood cellular therapy research. The PACT CPFs shall serve investigators within the scientific community as performance centers for translational research related to cellular therapies and manufacturers of cellular therapy products. PACT CPFs shall manufacture cellular therapy products for investigators from academia and industry needing manufacturing support. The cellular products manufactured by the CPFs are intended for non-clinical use within the United States.